ESC 365 - Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study

ESC Professional Premium Access

Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study

Session: Drug interactions, efficacy, and safety

Topic: Lipid-Lowering Agents

Speaker: Doctor A. Lai (Shatin, HK)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Doctor Angel Lai

The Chinese University of Hong Kong, Shatin (Hong Kong)

0 follower

7 more presentations in this session

Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity

Speaker: Mr J. Lee (Toronto, CA)

Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device

Speaker: Doctor K. Murata (Kobe, JP)

Drug-drug interactions of empagliflozin and dapagliflozin

Speaker: Professor C. Stoellberger (Vienna, AT)

Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study

Speaker: Mr S. Nielsen (Hellerup, DK)

Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis

Speaker: Doctor M. Abouzid (Poznan, PL)

Access the full session

Drug interactions, efficacy, and safety

Speakers: Doctor A. Lai, Mr J. Lee, Doctor K. Murata, Professor C. Stoellberger, Mr S. Nielsen...

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources